Vivesto Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Erik Kinnman

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.4yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.7yrs
Yönetim Kurulu ortalama görev süresi	4.9yrs

Son yönetim güncellemeleri

Recent updates

CEO

Erik Kinnman (66 yo)

1.4yrs

Görev süresi

cMr. Erik Kinnman, M.D., Ph D., M.B.A., Assoc. Prof., serves as Chief Executive Officer at Vivesto AB since January 23, 2023.He had been Chief Executive Officer at Sprint Bioscience AB (publ) since March...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Erik Kinnman	Chief Executive Officer	1.4yrs	Veri yok	Veri yok
Robert Maiorana	Head of Accounting & Acting CFO	1.9yrs	Veri yok	0.0037% SEK 5.9k
Urban Ekelund	IR Manager	no data	Veri yok	Veri yok
John Cosby	Head of Regulatory Affairs	18.4yrs	Veri yok	Veri yok
Dzianis Babrou	Head of Product Development	no data	Veri yok	Veri yok
Henrik Rönnberg	Chief Medical Officer of Animal Health	8.8yrs	Veri yok	Veri yok
Maria Hagberg	Head of Regulatory Affairs	5.2yrs	Veri yok	Veri yok
Heidi Ramstad	Chief Medical Officer	1.4yrs	Veri yok	Veri yok
Johanna Rostin	Chief Regulatory Officer	2.7yrs	Veri yok	Veri yok
Kia Bengtsson	Head of Clinical Development	2.7yrs	Veri yok	Veri yok
Teresa Zafra	Head of Preclinical Development & Clinical Operations	less than a year	Veri yok	Veri yok

2.7yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: 0N4A 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Göran Pettersson	Chairman of Business Advisory Board	4.9yrs	Veri yok	Veri yok
Hans Grönlund	Member of Scientific Advisory Board	4.9yrs	Veri yok	Veri yok
Mohammed Homman	Member of Business Advisory Board	4.9yrs	Veri yok	Veri yok
Jacob Kaluski	Member of Business Advisory Board	4.9yrs	Veri yok	Veri yok
Rolf Lewensohn	Chairman of Scientific Advisory Board	4.9yrs	Veri yok	Veri yok
Kerstin Strinnholm	Member of Business Advisory Board	5yrs	Veri yok	Veri yok
Pal Ryfors	Independent Director	2.1yrs	SEK 257.00k	Veri yok
Hege Hellstrom	Member of Business Advisory Board & Independent Director	4.9yrs	SEK 361.00k	Veri yok
Roger Tell	Independent Director	2.1yrs	SEK 218.00k	Veri yok
Ola Winqvist	Member of Scientific Advisory Board	4.9yrs	Veri yok	Veri yok
Peter Zonabend	Chairman of the Board	5.3yrs	SEK 612.00k	0.13% SEK 213.8k

4.9yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0N4A 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.9 yıldır).

Vivesto Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Vivesto AB (publ) Announces Composition of Nomination Committee

Vivesto AB Announces Appoints Erik Kinnman as CEO, Effective from January 23, 2023

Vivesto AB Announces Chief Executive Officer Changes, Effective No Later Than May 20, 2023

Vivesto AB Appoints Erik Kinnman as CEO

Vivesto AB Appoints Nomination Committee for 2023

Vivesto AB, Annual General Meeting, May 25, 2023

Recent updates

Vivesto's International Patent Application for XR-18 Receives Positive Decision

Vivesto AB's US Clinical Paccal Vet Trial Receives Approval to Start Patient Recruitment

Vivesto AB (publ) Announces Composition of Nomination Committee

Vivesto AB to Report Nine Months, 2024 Results on Nov 21, 2024

Vivesto AB Announces Early Termination of Patient Enrollment in the Investigator-Initiated Phase 1B Docetaxel Micellar Study

Vivesto AB Announces Appoints Erik Kinnman as CEO, Effective from January 23, 2023

Vivesto AB Announces Chief Executive Officer Changes, Effective No Later Than May 20, 2023

Vivesto AB Appoints Erik Kinnman as CEO

Vivesto AB Appoints Nomination Committee for 2023

Vivesto AB, Annual General Meeting, May 25, 2023

Vivesto AB Announces Resignation of Christer Nordstedt as Acting Ceo, Effective 30 November 2022

Second quarter 2022 earnings released

Vivesto AB Appoints Christer Nordstedt as Acting CEO

Vivesto AB Announces Chief Financial Officer Changes

Vivesto AB Announces CEO Francois Martelet Agrees on Ending the Employment Relationship, Effective July 21, 2022

First quarter 2022 earnings released: kr0.06 loss per share (vs kr0.10 loss in 1Q 2021)

Vivesto AB Announces Executive Changes

High number of new and inexperienced directors

Vivesto AB Appoints Daniel Tesfa as Chief Medical Officer

Oasmia Pharmaceutical AB announces step down of Fredrik Jarrsten as CFO

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Oasmia Pharmaceutical AB (Publ) Announces Update on Progress of Sakk Investigator-Initiated Phase 1B Trial of Docetaxel Micellar in Advanced Prostate Cancer

Oasmia Pharmaceutical Announces Progress on the Development of Its Next Generation XR-18 Drug Delivery Technology

High number of new and inexperienced directors

Independent Chairman recently bought kr53k worth of stock

Kazia Licenses Cantrixil, to Oasmia Pharmacetical AB

Fredrik JÃ¤rrsten to Join Oasmia Pharmaceutical AB (Publ) as CFO

Oasmia Pharmaceutical Appoints Dr. Heidi B. Ramstad as Chief Medical Officer

Oasmia Pharmaceutical AB (publ) Announces Proposed Class Action Settlement

Oasmia Pharmaceutical AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Oasmia Pharmaceutical AB (publ) to Report Q3, 2021 Results on Nov 18, 2021

Oasmia Pharmaceutical AB (Publ) Announces Board Appointments

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş